{"id":"https://openalex.org/W1972777034","doi":"https://doi.org/10.1097/00002030-200109280-00004","title":"CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients","display_name":"CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients","publication_year":2001,"publication_date":"2001-09-01","ids":{"openalex":"https://openalex.org/W1972777034","doi":"https://doi.org/10.1097/00002030-200109280-00004","mag":"1972777034","pmid":"https://pubmed.ncbi.nlm.nih.gov/11579237"},"language":"en","primary_location":{"id":"doi:10.1097/00002030-200109280-00004","doi":"https://doi.org/10.1097/00002030-200109280-00004","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002030-200109280-00004","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089780095","display_name":"Irini Sereti","orcid":"https://orcid.org/0000-0002-0076-0224","observed_orcids":["https://orcid.org/0000-0002-0076-0224"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irini Sereti","raw_affiliation_strings":["National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD 20892, USA","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109228413","display_name":"Betsey R. Herpin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Betsey Herpin","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043417594","display_name":"Julia A. Metcalf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julia A. Metcalf","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019780556","display_name":"Randy A. Stevens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randy Stevens","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040948574","display_name":"Michael Baseler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael W. Baseler","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088691739","display_name":"Claire W. Hallahan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Claire W. Hallahan","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018536389","display_name":"Joseph A. Kovacs","orcid":"https://orcid.org/0000-0002-5191-9880","observed_orcids":["https://orcid.org/0000-0002-5191-9880"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph A. Kovacs","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068358102","display_name":"Richard T. Davey","orcid":"https://orcid.org/0000-0002-3992-5524","observed_orcids":["https://orcid.org/0000-0002-3992-5524"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard T. Davey","raw_affiliation_strings":["Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017815904","display_name":"Henry Clifford Lane","orcid":"https://orcid.org/0000-0001-9509-1045","observed_orcids":["https://orcid.org/0000-0001-9509-1045"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210134534","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210155647","display_name":"National Institutes of Health Clinical Center","ror":"https://ror.org/04vfsmv21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210155647"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Clifford Lane","raw_affiliation_strings":["H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","accepted: 30 May 2001","revised: 22 March 2001"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. C. Lane, Clinical and Molecular Retrovirology Section, Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Rm 11S-231, 10 Center Drive MSC 1876, Bethesda MD 20892, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534"]},{"raw_affiliation_string":"Note:The US Government has been granted a use patent for intermittent IL-2 therapy including H. C. Lane and J. A. Kovacs as inventors","institution_ids":[]},{"raw_affiliation_string":"Sponsorship: This project has been funded in whole or in part with Federal funds under NCI contract No. NO1-CO-56000. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government","institution_ids":[]},{"raw_affiliation_string":"From the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, aScience Applications International Corp., Frederick, NCI, and the bCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda MD, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210134534","https://openalex.org/I4210140884","https://openalex.org/I4210155647"]},{"raw_affiliation_string":"accepted: 30 May 2001","institution_ids":[]},{"raw_affiliation_string":"revised: 22 March 2001","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.6747,"has_fulltext":false,"cited_by_count":53,"citation_normalized_percentile":{"value":0.82251359,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"15","issue":"14","first_page":"1765","last_page":"1775"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2711","display_name":"Emergency Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd4-t-cell-expansion","display_name":"CD4+ T cell expansion","score":0.8379999995231628},{"id":"https://openalex.org/keywords/interleukin-2-therapy","display_name":"interleukin-2 therapy","score":0.871999979019165},{"id":"https://openalex.org/keywords/t-cell-apoptosis","display_name":"T cell apoptosis","score":0.8489999771118164},{"id":"https://openalex.org/keywords/hiv-infection","display_name":"HIV infection","score":0.9020000100135803},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8389999866485596},{"id":"https://openalex.org/keywords/t-cell-activation-markers","display_name":"T cell activation markers","score":0.949999988079071},{"id":"https://openalex.org/keywords/hla-dr","display_name":"HLA-DR","score":0.8880000114440918},{"id":"https://openalex.org/keywords/cd38","display_name":"CD38","score":0.8659999966621399},{"id":"https://openalex.org/keywords/fas","display_name":"Fas","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cd25","display_name":"CD25","score":0.9200000166893005},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.8149999976158142},{"id":"https://openalex.org/keywords/gm-csf","display_name":"GM-CSF","score":0.9269999861717224},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.9739999771118164},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.9139999747276306},{"id":"https://openalex.org/keywords/highly-active-antiretroviral-therapy","display_name":"highly active antiretroviral therapy","score":0.9089999794960022},{"id":"https://openalex.org/keywords/pro-inflammatory-cytokines","display_name":"inflammatory cytokines","score":0.7580000162124634}],"concepts":[{"id":"https://openalex.org/C159912055","wikidata":"https://www.wikidata.org/wiki/Q14885119","display_name":"CD38","level":4,"score":0.7124053239822388},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.6382796764373779},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5720075368881226},{"id":"https://openalex.org/C164027704","wikidata":"https://www.wikidata.org/wiki/Q3491837","display_name":"Proinflammatory cytokine","level":3,"score":0.5641080737113953},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.5632128119468689},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5576794743537903},{"id":"https://openalex.org/C79484868","wikidata":"https://www.wikidata.org/wiki/Q5971673","display_name":"IL-2 receptor","level":4,"score":0.5521758794784546},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5047868490219116},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4648308753967285},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.4370046854019165},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.4136517643928528},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3544972240924835},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3424832820892334},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3190625309944153},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.19582119584083557},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.17928972840309143},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.07359451055526733},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.059041112661361694},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.053991228342056274},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015375","descriptor_name":"Receptors, Interleukin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015375","descriptor_name":"Receptors, Interleukin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015375","descriptor_name":"Receptors, Interleukin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015496","descriptor_name":"CD4-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D016130","descriptor_name":"Immunophenotyping","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016130","descriptor_name":"Immunophenotyping","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016130","descriptor_name":"Immunophenotyping","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018414","descriptor_name":"CD8-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D018414","descriptor_name":"CD8-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D018414","descriptor_name":"CD8-Positive T-Lymphocytes","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023241","descriptor_name":"Antiretroviral Therapy, Highly Active","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002030-200109280-00004","doi":"https://doi.org/10.1097/00002030-200109280-00004","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002030-200109280-00004","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},{"id":"pmid:11579237","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11579237","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS (London, England)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8399999737739563}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3029148","display_name":null,"funder_award_id":"N01 CO 56000","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G588003333","display_name":"OPERATIONS &TECHNICAL SUPPORT","funder_award_id":"n01co056000-057","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"}],"funders":[{"id":"https://openalex.org/F4320306085","display_name":"U.S. Department of Health and Human Services","ror":"https://ror.org/033jnv181"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W1588713146","https://openalex.org/W1967239571","https://openalex.org/W1970128046","https://openalex.org/W1977074734","https://openalex.org/W1978196981","https://openalex.org/W1991955183","https://openalex.org/W1996032364","https://openalex.org/W1997196319","https://openalex.org/W2013068560","https://openalex.org/W2022098233","https://openalex.org/W2027548834","https://openalex.org/W2031777513","https://openalex.org/W2036898193","https://openalex.org/W2045837677","https://openalex.org/W2057178907","https://openalex.org/W2065158430","https://openalex.org/W2066805431","https://openalex.org/W2066993659","https://openalex.org/W2067601243","https://openalex.org/W2076597201","https://openalex.org/W2078532650","https://openalex.org/W2088564232","https://openalex.org/W2091971455","https://openalex.org/W2110819064","https://openalex.org/W2114866206","https://openalex.org/W2125052178","https://openalex.org/W2125311191","https://openalex.org/W2127031590","https://openalex.org/W2137384756","https://openalex.org/W2139551787","https://openalex.org/W2159531745","https://openalex.org/W2160488250","https://openalex.org/W2165141877","https://openalex.org/W2172227861","https://openalex.org/W2295968329","https://openalex.org/W2322485212","https://openalex.org/W2325477384","https://openalex.org/W2334332481","https://openalex.org/W2334980131","https://openalex.org/W2404956728","https://openalex.org/W2564152524"],"related_works":["https://openalex.org/W42562563","https://openalex.org/W2027999423","https://openalex.org/W127140033","https://openalex.org/W2132735695","https://openalex.org/W1992999743","https://openalex.org/W2398341294","https://openalex.org/W2041201944","https://openalex.org/W2362506364","https://openalex.org/W2064440970","https://openalex.org/W2015095588"],"abstract_inverted_index":{"OBJECTIVE":[0],"AND":[1],"DESIGN:":[2],"In":[3],"an":[4,203],"attempt":[5],"to":[6,37,192],"determine":[7],"the":[8,11,42,55,79,88,125,207,232,236,243,248,255],"mechanisms":[9],"underlying":[10],"CD4":[12,48,130,147,159,197,208,244],"T":[13,51,95,133,150,160,200,209,222],"cell":[14,52,210,262,265],"expansions":[15,245],"in":[16,47,99,172,187,247,260],"patients":[17,28,62,174,190],"receiving":[18,64],"intermittent":[19,251],"interleukin":[20],"(IL)-2,":[21],"a":[22,32],"cohort":[23],"of":[24,35,40,44,58,81,90,94,103,129,139,164,182,195,206,218,227,250,258],"10":[25],"HIV":[26,188],"infected":[27,189],"were":[29,63,74,97,116,170],"studied":[30],"during":[31,235],"5-day":[33],"cycle":[34],"IL-2":[36,82,123,183,237,252],"measure":[38],"rates":[39,128],"apoptosis,":[41],"expression":[43],"activation":[45,214,219],"markers":[46,220],"and":[49,54,77,111,131,142,148,167,198,224,229,264],"CD8":[50,132,149,199],"subsets":[53],"serum":[56,165],"levels":[57,102,169,226],"proinflammatory":[59],"cytokines.":[60],"All":[61],"highly":[65],"active":[66],"antiretroviral":[67],"therapy.":[68],"METHODS:":[69],"Peripheral":[70],"blood":[71],"mononuclear":[72],"cells":[73,201,223],"tested":[75,117],"pre-":[76],"at":[78],"completion":[80],"treatment":[83],"with":[84,216],"annexin":[85],"V/7-AAD":[86],"for":[87,184],"measurement":[89],"apoptosis.":[91],"Phenotypic":[92],"analyses":[93],"lymphocytes":[96,134,151],"performed":[98],"parallel.":[100],"Serum":[101],"interferon":[104],"(IFN)gamma,":[105],"granulocyte-macrophage":[106],"colony":[107],"stimulating":[108],"factor,":[109],"IL-6":[110,166,230],"tumor":[112],"necrosis":[113],"factor":[114],"(TNF)alpha":[115],"by":[118],"enzyme-linked":[119],"immunosorbent":[120],"assay.":[121],"RESULTS:":[122],"increased":[124,144,233],"spontaneous":[126],"apoptosis":[127,194,234],"(P":[135],"=":[136],"0.003).":[137],"Expression":[138],"HLA-DR,":[140],"CD38":[141],"CD95":[143],"on":[145,158,221],"both":[146,196,261],"whereas":[152,175],"CD25":[153],"induction":[154,217],"was":[155],"observed":[156],"exclusively":[157],"cells.":[161],"Significant":[162],"increases":[163,259],"TNFalpha":[168,228],"noted":[171],"all":[173],"viral":[176],"loads":[177],"remained":[178],"unchanged.":[179],"CONCLUSION:":[180],"Administration":[181],"5":[185],"days":[186],"leads":[191],"enhanced":[193],"despite":[202],"eventual":[204],"increase":[205],"count.":[211],"A":[212],"profound":[213],"state":[215],"high":[225],"accompanies":[231],"cycle.":[238],"These":[239],"data":[240],"suggest":[241],"that":[242],"seen":[246],"context":[249],"therapy":[253],"are":[254],"net":[256],"result":[257],"proliferation":[263],"death.":[266]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}